TacticScaleWhat HUTCHMED (China) Does & How It Makes Money (0013.HK)
Updated October 2026 · reflects HUTCHMED (China)'s latest reported financials
Hong Kong biotech developing and selling targeted cancer and immune-disease drugs. It earns money by selling its approved drugs and through collaboration agreements with partners such as AstraZeneca, Lilly, Takeda and Innovent, which help develop and bring its medicines to market.
How HUTCHMED (China) makes money
It earns money by selling its approved drugs and through collaboration agreements with partners such as AstraZeneca, Lilly, Takeda and Innovent, which help develop and bring its medicines to market.
What HUTCHMED (China) does
HUTCHMED (China) Limited, formerly Hutchison China MediTech, is a Hong Kong-headquartered biopharmaceutical company founded in 2000. It discovers, develops and commercializes targeted therapies and immunotherapies for cancer and immunological diseases. Its main drugs include fruquintinib, a VEGFR inhibitor for colorectal and other cancers; savolitinib, a MET inhibitor for lung, kidney and gastric cancers; and surufatinib for neuroendocrine tumors. The pipeline also covers blood disorders and blood cancers, including sovleplenib for immune thrombocytopenia, ranosidenib for acute myeloid leukemia, and the early-stage candidates HMPL-760 and HMPL-506. Partnerships with AstraZeneca, Lilly, Takeda, Innovent, Inmagene and Epizyme support its development and commercial reach.
Products & services
- Fruquintinib
- Savolitinib
- Surufatinib
- Sovleplenib
- Tazemetostat
- Fanregratinib
What is HUTCHMED (China) worth?
A reliable owner-earnings fair value isn't available for this company yet — we'd rather say so than print a number we don't trust.
We show a fair value only when the method is trustworthy. See HUTCHMED (China) on TacticScale →